# MRI Screening for Brain Metastases Among Patients With Triple Negative or HER2+ Stage II or III Breast Cancer

> **NCT06247449** · NA · RECRUITING · sponsor: **Sunnybrook Health Sciences Centre** · enrollment: 100 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DIAGNOSTIC_TEST:** Brain imaging
- **DIAGNOSTIC_TEST:** Analysis of circulating tumor DNA
- **BEHAVIORAL:** Testing Morbidities Index

## Key facts

- **NCT ID:** NCT06247449
- **Lead sponsor:** Sunnybrook Health Sciences Centre
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-11-29
- **Primary completion:** 2027-06-01
- **Final completion:** 2028-06-01
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2025-12-18

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06247449

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06247449, "MRI Screening for Brain Metastases Among Patients With Triple Negative or HER2+ Stage II or III Breast Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06247449. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*